K-numberK250225
Device nameBolt Intravascular Lithotripsy (IVL) System
ApplicantBolt Medical, Inc.
Product codePPN
Device classClass II
Decision dateMar 25, 2025
DecisionSubstantially Equivalent
Regulation870.1250
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Bolt Intravascular Lithotripsy (IVL) System is a balloon catheter and console that enhances peripheral artery angioplasty by delivering pulsatile mechanical energy (lithotripsy) to calcified lesions before balloon inflation at low pressure. It is intended for treatment of calcified stenotic lesions in peripheral arteries (iliac, femoral, popliteal, and infra-popliteal), but not for coronary, carotid, or cerebral use.

Technological characteristics

The Bolt IVL System incorporates substantially equivalent design, dimensional, and performance specifications to the predicate Shockwave Lithoplasty System, including identical sheath and guidewire compatibility, usable catheter length, balloon diameters and lengths, and treatment and nominal pressures. Both systems use catheters delivering acoustic energy via cable to a console with the same operating principles and intended use.

Test standards cited

ISO 10993-1:2020 (Biological evaluation of medical devices); 21 CFR 58 Good Laboratory Practices. Testing included catheter mechanical properties (diameter, tensile strength, kink resistance, torsional strength, compliance, fatigue), balloon performance (inflation/deflation time, burst strength), pushability, trackability, fluoroscopic visibility, particulate evaluation, console hardware and electrical performance, electromagnetic compatibility, and software verification/validation.

Substantial equivalence argument

The Bolt IVL System shares the same intended use, mechanism of action, and similar technological characteristics as the predicate device (Shockwave Lithoplasty System K161384). Both deliver acoustic energy to peripheral arteries via catheter-console systems for lithotripsy-enhanced angioplasty. Any design differences were evaluated through comprehensive bench testing, chronic porcine animal studies, and two prospective clinical trials (RESTORE ATK and RESTORE BTK) that demonstrated safety and effectiveness meeting or exceeding performance goals, with no new safety or effectiveness questions identified.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →